MA-EVERBRIDGE
25.1.2021 13:32:08 CET | Business Wire | Press release
Everbridge , Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM ), today announced COVID-19 Shield™: Vaccine Distribution , an extension to its CEM platform offering risk insights, logistics awareness and vaccine appointment management to support the full spectrum of organizations that develop, manufacture, transport, distribute, regulate, and administer the coronavirus vaccine. The offering also provides governments with a single, unified platform to expedite vaccine coordination, communication and distribution for all residents, including vulnerable populations with special needs. Representing significant adoption for its vaccine distribution software, Everbridge announced the deployment of its CEM Platform to power the digital vaccination distribution system for a variety of municipalities and organizations, including the entire state population of West Virginia , and the County of Sarasota, Florida , among others.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005258/en/
“We have partnered with Everbridge,” said Governor Jim Justice of West Virginia in a recent press conference for state residents. “Everbridge helps states notify their citizens when there’s a fire, a flood, or a hurricane, but now they are going to help us coordinate vaccines as we can get them from the federal government. We will be the first state to turn on this new vaccine scheduling system. Everbridge helped us stand this up in one week’s time.”
In the U.S., healthcare experts have stated : “at a pace of one million doses a day, the virus wouldn’t be contained until sometime in 2022.” A recent survey also reveals that 6 in 10 Americans do not know when or where to get the vaccine. In addition, the logistics of moving this type of vaccine across the country in a short period of time creates a substantial challenge , especially given the cruciality of cold chain monitoring .
Added Gov. Justice, “This system [provides residents] the ability to put your information in directly and helps us coordinate when vaccines are available to notify you when and where to come to get your vaccine. You will get a message back after you’ve registered to confirm that you are in the system and we will send you updates regularly. The system sends emails, texts, and phone calls. Whatever way you want us to notify you about your availability, [Everbridge] will let you pick up on just that.”
“During a pandemic, efficient, expeditious and equitable distribution and administration of [the] approved vaccine is critical,” as stated by the U.S. Centers for Disease Control and Prevention (CDC) in their recent guidelines . Everbridge’s new COVID-19 Shield™: Vaccine Distribution software offers federal, state and local governments as well as businesses and healthcare systems new capabilities to: better manage vaccine supply chains amidst other concurrent critical events, analyze risk of virus spread, avoid operational disruptions, and ensure the smooth rollout of vaccines to employees and citizens with easy-to-deploy software integrations.
For governments, Everbridge enables state, city and county leaders to rapidly coordinate communication across the population, automate appointment signup and monitor registrations, track vaccine availability, ensure doses are shipped to proper facilities to avoid spoilage, and enable citizen scheduling to avoid long waits and call center challenges.
Demonstrating the extreme pent up demand and need for technology to assist in the communications, scheduling and distribution of the vaccine, the County of Sarasota, Florida leveraged Everbridge’s vaccine distribution software to enable 50,000 residents to sign up for the COVID-19 vaccine in the first hour of launch, which has been reported as ‘a giant leap forward.’ “We are utilizing Everbridge to coordinate the vaccine distribution in our community,” said Rich Collins, Director of Sarasota County Emergency Services. “The system aids in tracking and prioritizing this process, which allows us to serve our vulnerable populations and frontline workers.”
“We applaud Governor Justice and the state of West Virginia for their leadership in applying best practices to help keep their citizens safer and accurately informed through effective vaccine distribution. Solving this public health crisis faster will unlock the ability for governments to fully re-open economies for the betterment of all states, people and businesses,” said David Meredith, CEO of Everbridge. “The expansion of the Everbridge critical event management software platform to include vaccine distribution creates new ways for government, healthcare and all types of businesses to automate logistics, maintain vital communications and keep people safe during this crucial rollout.”
With Everbridge’s COVID-19 Shield™: Vaccine Distribution, enterprise customers gain capabilities to: coordinate the number of employees who have been vaccinated, manage population density and access to office buildings based on vaccination status, and receive timely alerts when employees report signs of illness so they can quickly respond to safeguard staff and visitors.
“Garnet Healthcare is providing mobile COVID testing and care across Vermont, New York, and Massachusetts,” said Ryan Ferris, CEO & Co-founder at Garnet Healthcare , which provides patient logistics, care coordination, and clinical diagnostics to healthcare institutions, corporate clients, and governmental agencies across New England. “Everbridge’s CEM Platform provides situational awareness of threats to our clinical logistics which could inhibit or delay these critical services. In addition, the platform provides coordination support to help us manage the testing process and follow-up with patients supporting our end-to-end clinical services.”
The new Everbridge COVID-19 Shield™: Vaccine Distribution software solution includes the following features among the suite’s broader CEM capabilities:
- Enhanced COVID-19 Risk Feed showcasing vital real-time information, including the incidence of new virus strains and vaccine related intelligence;
- Crisis Management Module to follow, log and audit the transport, handling, and/or administration of the vaccine;
- Vaccine Distribution Logistics Service to provide situational awareness to better manage vaccine supply chains;
- Customized Employee Surveys to help confirm whether employees have received the vaccine;
- Appointment Management Tool to help manage the scheduling, tracking and communications of vaccine administration; and
- Out-of-Box Workflows in Smart Orchestration to help improve distribution management, such as vaccine appointment follow-ups.
“Everbridge helps to bridge the gap between the public sector and the private sector,” said Mark Aprigliano, Senior Director, Public Safety at Jackson Health System . “Their CEM Platform provides situational awareness of threats to the supply chain for the vaccine which could inhibit or delay distribution. It also provides a common operating picture to all of the stakeholders in that supply chain, providing visibility and a coordinated effort from manufacturing to point of vaccination.”
To learn more best practices for distribution and management of the vaccine rollout, join Everbridge and Dr. Scott Gottlieb, former U.S. Food & Drug Administration Commissioner for a discussion entitled “The End of the Pandemic: Successful Vaccine Distribution ” on Wednesday, January 27, 2021 at 11:30 a.m. ET.
About Everbridge
Everbridge, Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order Keep People Safe and Businesses Running™. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,400 global customers rely on the Company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication devices, and track progress on executing response plans. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 8 of the 10 largest global automakers, 9 of the 10 largest U.S.-based health care providers, and 7 of the 10 largest technology companies in the world. Everbridge is based in Boston with additional offices in 20 cities around the globe. For more information visit www.everbridge.com
Cautionary Language Concerning Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 28, 2020. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210125005258/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software26.6.2026 23:28:00 CEST | Press release
Powered by the risk-centric PASTA methodology and two decades of accredited offensive security, the integrated platform lets enterprises threat model in a security sprint—then prove the risk through AI-led, human-on-the-loop testing. VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained s
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 22:30:00 CEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
